SNY: 赛诺菲集团

SNY新闻

• 13:28 What To Expect From Sanofi In Q1 2026 (NASDAQ:SNY)
• 13:03 Merck Secures EU Nod for RSV Antibody Enflonsia in Infants
• 17:38 DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
• 14:42 Johnson & Johnson: Why I See Downside Ahead (NYSE:JNJ)
• 18:47 Protalix: Elfabrio Struggles Against Oral Competition (NYSE:PLX)
• 17:00 Regeneron Boosts Cancer Pipeline Through Telix Collaboration
• 13:44 SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
• 18:27 Denali Stock Falls as Partner Takeda Ends Collaboration Deal
• 15:57 SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema
• 19:06 Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
• 02:38 ANI Pharmaceuticals Stock: Worthy Of A Position (NASDAQ:ANIP)
• 16:12 Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
• 15:45 How Merck's New Cholesterol Buster Will 'Move The Needle' 'By Removing The Needle'
• 12:41 AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
• 22:21 Top Research Reports for Palantir, Linde and Arista Networks
• 18:25 Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• 16:00 REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
• 14:54 Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone (APGE)
• 13:59 How Apogee, Up Almost 20%, Plans To Take On Rival Regeneron's Eczema Drug
• 11:30 Dupixent's Impact On Sanofi: A Quantitative Projection Of Its Revenue (NASDAQ:SNY)
• 20:10 Top Stock Reports for GE Aerospace, Shell & McKesson
• 18:18 Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms (NASDAQ:SYRE)
• 20:09 Factbox-US Health Secretary Kennedy’s vaccine actions and policy positions
• 19:35 US judge blocks efforts to reshape childhood vaccine policy